Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
New Medicare Legislation Aims to Accelerate Coverage of Medical Devices, Make Telehealth Flexibilities Permanent
New legislation building on the 21st Century Cures Act of 2016 would accelerate coverage of medical devices under Medicare. It would also permanently remove...
U.S. Insurers Asked to Report Prescription Drug Cost Data to Federal Government
An interim final rule issued by the Biden administration will require private insurers to report prescription drug costs to the U.S. federal government.
Under the...
Beti-Cel Granted Priority Review for Beta Thalassemia
The U.S. Food and Drug Administration (FDA) has accepted bluebird bio’s Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review.
Beti-cel is a...
Adding All-Trans Retinoic Acid to Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
A combination regimen comprising all-trans retinoic acid (ATRA) plus low-dose rituximab was associated with an 80% overall response rate and a 61% sustained response...
Liso-Cel Shows Promising Safety and Efficacy in Relapsed/Refractory CLL/SLL
In patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), treatment with lisocabtagene maraleucel (liso-cel) was associated with deep, rapid responses...
Current Issue
December 2021 Volume 7 Issue 15
This issue explores doctor deserts, celebrates the 50th anniversary of the National Cancer Act, and more.